All tenders
75A50121C00077

THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN

Office of Assistant Secretary for Preparedness and Response · United States

This contract has been awarded. Browse open opportunities
View Source

Time Left to Bid

Awarded

AwardedHealthcare & MedicalFederal

Basic information

Reference number
75A50121C00077
Government level
Federal
Solicitation type
Healthcare & Medical
Title
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
Source ID
usa-75A50121C00077

Details

Location
United States

Description

THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN Awarded to: INTERNATIONAL AIDS VACCINE INITIATIVE INC. Agency: Department of Health and Human Services Sub-agency: Office of Assistant Secretary for Preparedness and Response Award type: DEFINITIVE CONTRACT

Dates

Publication
2021/09/30 12:00:00 AM UTC
Closing date
2028/12/31 12:00:00 AM UTC

Estimated value

$95.6M USD

Classification

Normalized category

Healthcare & Medical

Source: USASpending (Federal)

Last updated 2026-09-02, 1:10:52 a.m.

Data refreshed every 2 hours